Citations

Showing 10 of 108094 citations.

Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention
Hantel, Andrew , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Stock, Wendy , Mandrekar, Sumithra J. , Larson, Richard A. , Stone, Richard M. , Lathan, Christopher S. , Byrd, John C. , Abel, Gregory A. , Byrd, John C. , Jacobson, Sawyer , Mandrekar, Sumithra J , Larson, Richard A , Stone, Richard M , Byrd, John C , Abel, Gregory A , Stock, Wendy , Byrd, John C , DeAngelo, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2022 | Volume: 40 | Issue: 32 | Pages: 3709-3718

10.1200/jco.22.00307 | PMID 35696629 Get It

PURPOSE Representativeness in acute leukemia clinical research is essential for achieving health equity. The National Cancer Institute's mandate for Comprehensive Cancer Centers (CCCs) to define and assume responsibility for cancer control and treatment across a geographic catchment area provides an enforceable mechanism to target and potentially remediate participatory inequities. METHODS We examined enrollee characteristics across 15 Cancer and Leukemia Group B/Alliance cooperative group adult acute leukemia clinical trials (N = 3,734) from 1998 to 2013, including participation in optional companion biobanks. We determined enrollment odds by race-ethnicity for all participants adjusted for national incidence, and for those enrolled at CCCs adjusted for catchment area incidence. We modeled biobank participation by sociodemographics using logistic regression. RESULTS Non-Hispanic (NH)-White patients were more likely to be enrolled than NH-Black, NH-Asian, or Hispanic patients (odds ratio [OR], 0.75, 0.48, and 0.44, respectively; all P < .001), but less likely than NH-Native American patients (OR, 1.91; P < .001), adjusted for national incidence. Enrollment odds were lower for NH-Black, NH-Asian, and Hispanic patients at CCCs adjusted for catchment area incidence (OR, 0.57, 0.26, and 0.32, respectively; P < .001); differences were driven by overenrollment of NH-White patients from outside self-defined catchment areas (18.1% v 12.3%; χ2 P = .01) and by CCCs with less absolute enrollee diversity (rank sum P = .03). Among all enrollees, NH-White race-ethnicity and lower neighborhood deprivation correlated with biobank participation (OR, 1.81 and 1.45, respectively; P = .01 and .03). For CCC enrollees, the correlation of race-ethnicity with biobank participation was attenuated by a measure accounting for their site's degree of enrollment disparity but not neighborhood deprivation. CONCLUSION Acute leukemia clinical research disparities are substantial and driven by structural trial enrollment barriers at CCCs. Real-time CCC access and enrollment monitoring is needed to better align research participation with local populations.
A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitors
Liu, Xin , Harrington, Susan M. , Hirdler, Jacob B. , Gicobi, Joanina K. , Zhu, Xingxing , Yan, Yiyi , Hsu, Michelle A. , Barham, Whitney , Hsu, Michelle, Zeng, Hu , Pavelko, Kevin D. , Mansfield, Aaron S. , Dong, Haidong

Mayo Clinic

No container title available | June 13, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1659209/v1 Get It

Abstract Seven different anti-PD-1 and PD-L1 monoclonal antibodies are now widely used in the US to treat a variety of cancer types, but there have been no clinical trials comparing them directly. Furthermore, because many of these antibodies do not cross react between mouse and human proteins, no preclinical models exist in which to consider these types of questions. Thus, we produced humanized PD-1 and PD-L1 mice in which the extracellular domains of both mouse PD-1 and PD-L1 were replaced with the corresponding human sequences. Using this new model, we sought to compare the strength of the immune response generated by FDA-approved antibodies. To do this, we performed an in vivo T cell priming assay in which anti-PD-1/L1 therapies were given at the time of T cell priming against surrogate tumor antigen (OVA), followed by subsequent B16-OVA tumor challenge. We found that anti-PD-1/L1-treated mice exhibited significantly better tumor rejection than controls, although both the control and antibody-treated mice generated comparable numbers of OVA-specific T cells at the time of priming. To determine what could mediate this strong antitumor immune response, we identified the increased production of CX3CR1+PD-1+CD8+ cytotoxic T cells in the anti-PD-1/L1-treated mice, the same subset of effector T cells known to increase in clinical responders to PD-1/L1 therapy. Thus, our model permits the direct comparison of FDA-approved anti-PD-1/L1 monoclonal antibodies and further correlates successful tumor rejection with the level of CX3CR1+PD-1+CD8 + T cells, making this model a critical tool for future studies to optimize and better utilize anti-PD-1/L1 therapeutics.
Assessment of the Use of Sex and Gender Terminology in US Federal, State, and Local Databases
Jacobs, Jeremy W. , Bibb, Lorin A. , Shelton, K. Maureen, Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett

Mayo Clinic

JAMA Internal Medicine | June 13, 2022 | Volume: 182 | Issue: 8 | Pages: 878

10.1001/jamainternmed.2022.2026 | PMID 35696137 Get It

The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
Brunklaus, Andreas , Brünger, Tobias , Feng, Tony, Lehikoinen, Anni , Panagiotakaki, Eleni , Vințan, Mihaela Adela , Symonds, Joseph D. , Andrew, James E., Delima, Sarah , Gallois, Julie, Hanrahan, Donncha, Macleod, Stewart, Marjanović, Dragan , McTague, Amy , Nuñez-Enamorado, Noemi, Pérez‐Palma, Eduardo , Perry, Μ. Scott , Pysden, Karen, Russ-Hall, Sophie , Scheffer, Ingrid E. , Sully, Krystal , Syrbe, Steffen , Vaher, Ulvi , Velayutham, Murugan, Vogt, Julie , Weiss, Shelly K. , Zuberi, Sameer M. , Lal, Dennis , Møller, Rikke S. , Mantegazza, Massimo , Symonds, Joseph , Zuberi, Sameer M , Mantegazza, Massimo , Brunklaus, Andreas , Scheffer, Ingrid E , Møller, Rikke S , Fons, Carmen , Andrew, James, Arzimanoglou, Alexis , Lesca, Gaëtan , Núñez‐Enamorado, Noemí , Wirrell, Elaine , Cestèle, Sandrine

Mayo Clinic

Brain | June 13, 2022 | Volume: 145 | Issue: 11 | Pages: 3816-3831

10.1093/brain/awac210 | PMID 35696452 Get It

Abstract Brain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4–69.3; P = 1.3 × 10−7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
Transvaginal Approach to Surgery for Pelvic Organ Prolapse
Maldonado, Darlene Vargas, Chen, Anita H. , Gebhart, John B.

Mayo Clinic

Journal of Gynecologic Surgery | June 13, 2022 | Volume: 39 | Issue: 1 | Pages: 12-18

10.1089/gyn.2022.0033 Get It

Increased incidence of pediatric narcolepsy following the 2009 H1N1 pandemic: a report from the pediatric working group of the sleep research network
Simakajornboon, Narong , Maski, Kiran , Owens, Judith , Rosen, Carol L. , Ibrahim, Sally , Hassan, Fauziya, Chervin, Ronald D., Perry, Gayln V., Brooks, Lee J., Mason, Thornton, Shelton, Althea Robinson , Malow, Beth A. , Naqvi, Kamal, Chen, Maida L. , Jambhekar, Supriya, Halbower, Ann C., Graw-Panzer, Katharina, Dayyat, Ehab , Lew, Jenny , Melendres, Cecilia, Kotagal, Suresh , Jain, Sejal V. , Super, Elizabeth, Dye, Thomas J. , Hossain, Md Monir , Tadesse, Dawit G. , Maski, Kiran , Rosen, Carol , Gozal, David , Dye, Thomas , Mignot, Emmanuel , Gozal, David , Chen, Maida Lynn

Mayo Clinic

Sleep | June 13, 2022 | Volume: 45 | Issue: 9 | Pages: No page available

10.1093/sleep/zsac137 | PMID 35695235 Get It

Abstract This study was aimed to evaluate the yearly incidence of pediatric narcolepsy prior to and following the 2009 H1N1 pandemic and to evaluate seasonal patterns of narcolepsy onset and associations with H1N1 influenza infection in the United States. This was a multicenter retrospective study with prospective follow-up. Participants were recruited from members of the Pediatric Working Group of the Sleep Research Network including 22 sites across the United States. The main outcomes were monthly and yearly incident cases of childhood narcolepsy in the United States, and its relationship to historical H1N1 influenza data. A total of 950 participants were included in the analysis; 487 participants were male (51.3%). The mean age at onset of excessive daytime sleepiness (EDS) was 9.6 ± 3.9 years. Significant trend changes in pediatric narcolepsy incidence based on EDS onset (p &lt; .0001) occurred over the 1998–2016 period, peaking in 2010, reflecting a 1.6-fold increase in narcolepsy incidence. In addition, there was significant seasonal variation in narcolepsy incident cases, with increased cases in spring (p &lt; .05). Cross-correlation analysis demonstrated a significant correlation between monthly H1N1 infection and monthly narcolepsy incident cases (p = .397, p &lt; .0001) with a lag time of 8 months. We conclude that there is a significant increase in pediatric narcolepsy incidence after the 2009 H1N1 pandemic in the United States. However, the magnitude of increase is lower than reported in European countries and in China. The temporal correlation between monthly H1N1 infection and monthly narcolepsy incidence, suggests that H1N1 infection may be a contributing factor to the increased pediatric narcolepsy incidence after the 2009 H1N1 pandemics.
Pulmonary Artery Angiomatoid Fibrous Histiocytoma Mimicking a Large Pulmonary Embolism
Haug, Logan P. , Zarka, Matthew A., D’Cunha, Jonathan, Downey, Francis X. , Seetharam, ­Mahesh , Yang, Ming

Mayo Clinic

Clinical Nuclear Medicine | June 13, 2022 | Volume: 47 | Issue: 12 | Pages: e738-e739

10.1097/rlu.0000000000004306 | PMID 35695721 Get It

Abstract A 39-year-old man presented with progressive dyspnea and lower extremity edema. Doppler ultrasound demonstrated bilateral leg partially occluded venous thromboses. A V/Q scan revealed a mismatched perfusion defect involving the entire right middle and lower lobes. Subsequent CT pulmonary angiogram revealed a mass lesion occluding the right interlobar pulmonary artery. Endobronchial ultrasound–guided fine-needle aspiration of the mass was concerning for neoplasm. 18 F-FDG PET/CT demonstrated marked hypermetabolism of the mass lesion. Patient underwent transmediastinal right pneumonectomy with histopathologic diagnosis of pulmonary artery angiomatoid fibrous histiocytoma, a rare etiology mimicking large pulmonary artery embolism.
Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients
Lecendreux, Michel , Rosen, Carol L. , Ruoff, Chad , Black, Jed , Parvataneni, Rupa, Guinta, Diane, Wang, Y. Grace, Ruoff, Chad M , Plazzi, Giuseppe , Dauvilliers, Yves , Mignot, Emmanuel

Mayo Clinic

Journal of Clinical Sleep Medicine | June 13, 2022 | Volume: 18 | Issue: 9 | Pages: 2217-2227

10.5664/jcsm.10090 | PMID 35689598 Get It